Download full-text PDF

Source
http://dx.doi.org/10.1002/ppul.26611DOI Listing

Publication Analysis

Top Keywords

clinical pulmonary
4
pulmonary gene
4
gene protein
4
protein expression
4
expression levels
4
levels infant
4
infant lethal
4
lethal abca3
4
abca3 variants
4
clinical
1

Similar Publications

Background: Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, with the worst prognosis among all subtypes. The impact of distinct cell subpopulations within the tumor microenvironment (TME) on TNBC patient prognosis has yet to be clarified.

Methods: Utilizing single-cell RNA sequencing (scRNA-seq) integrated with bulk RNA sequencing (bulk RNA-seq), we applied Cox regression models to compute hazard ratios, and cross-validated prognostic scoring using a GLMNET-based Cox model.

View Article and Find Full Text PDF

Background: Inflammation and immune evasion are associated with tumorigenesis and progression. The Systemic Inflammation Response Index (SIRI) has been proposed as a pre-treatment peripheral blood biomarker. This study aims to compare the relationship between SIRI, various serum biomarkers, and the prognosis of NSCLC patients before and after treatment.

View Article and Find Full Text PDF

An approach to COVID‑19 and oncology: From impact, staging and management to vaccine outcomes in cancer patients: A systematic review and meta‑analysis.

Exp Ther Med

February 2025

Oncology Department, Princess Noorah Oncology Center, King Abdul Aziz Medical City, Ministry of National Guard-Health Affairs, King Abdullah International Medical Research Centre, College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Makkah-Jeddah Highway Road, Jeddah 22384, Saudi Arabia.

The COVID-19 pandemic has had a global impact, with >771 million confirmed cases and 6 million deaths reported by October 2023. Cancer patients, due to their immunosuppressed status, face an increased infection risk and higher COVID-19 complications. The present study aimed to assess clinical outcomes in COVID-19-infected cancer patients, focusing on mortality rates and other aspects, providing valuable insight for better protection and outcomes.

View Article and Find Full Text PDF

VA-ECOM assisted percutaneous mechanical thrombectomy treatment high-risk pulmonary embolism.

Front Cardiovasc Med

December 2024

Department of Vascular Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.

Background: Percutaneous mechanical thrombectomy (PMT) is increasingly used in the treatment of intermediate and high-risk acute pulmonary embolism (PE), and the treatment of high-risk PE with the aid of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has also been reported. However, there are few reports of VA-ECOM-assisted PMT in the treatment of high-risk PE. The purpose of this study is to summarize the data of 11 patients with high-risk PE treated with VA-ECMO assisted PMT, and propose feasible treatment methods for such patients.

View Article and Find Full Text PDF

Fecal microbiota transplantation in severe pneumonia: a case report on overcoming pan-drug resistant infection.

Front Med (Lausanne)

December 2024

Department of Respiratory and Critical Care Medicine, Fuzong Clinical Medical College of Fujian Medical University, Dongfang Hospital of Xiamen University, The 900th Hospital of Joint Logistics Support Force, Fuzhou, China.

Objective: To evaluate the therapeutic potential of fecal microbiota transplantation (FMT) in treating severe pneumonia patients with concurrent pan-drug resistant infection.

Methods: A case report of a 95-year-old female patient with severe pneumonia, complicated by pan-resistant bacterial infections, is presented. The patient was diagnosed with severe pneumonia caused by COVID-19, along with co-infections of , , , , ESBL-producing pan-drug resistant and pan-resistant .

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!